搜尋結果 "#ovariancarcinoma"

動態

查看更多結果

Mary Grace N. Tamio shared news

在 October 11 2023 at 02:27 PM 已編輯

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas

#immunohistochemistry #ovariancarcinoma #journals #articles

More info | ⬇️

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas
ObjectiveInhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer typ...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio shared news

在 August 15 2022 at 10:09 PM 已編輯

A Multistep Tumor Growth Model of High Grade Serous Ovarian Carcinoma Identifies Hypoxia Associated Signatures

#tumor #ovariancarcinoma #hypoxia #journals #articles

For more information | ⬇️

A Multistep Tumor Growth Model of High Grade Serous Ovarian Carcinoma Identifies Hypoxia Associated Signatures
High-grade serous ovarian carcinoma (HGSC) is associated with late-stage disease presentation and poor prognosis, with lim...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio

在 February 04 2022 at 06:50 PM 已編輯

Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma

#trametinib #ovariancarcinoma

For more information | ⬇️
https://cn1699.com/news/trametinib-represents-potential-new-standard-care-patients-recurrent-low-grade-serous-ovarian

Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma | CN1699
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of...
0 0 0 0 0 0 0

留言

Like

分享

搜尋過濾器

搜尋結果 "#ovariancarcinoma"

動態